Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

ILX-651 enters new phase II study in melanoma

Oct. 10, 2003

Novel heparanase inhibitors and their use as antitumor agents described in recent patent

Oct. 9, 2003

News-breaking molecule: the first and only reported potent inhibitor of human asparagine synthase

Oct. 9, 2003

Antitumor efficacy and safety of arzoxifene in advanced endometrial cancer

Oct. 8, 2003

Sequential combination therapy reported effective in advanced follicular lymphoma

Oct. 8, 2003

Arius and PDL enter cancer antibody development partnership

Oct. 6, 2003

Rolling NDA submission continues for RSR-13

Oct. 6, 2003

Bayer presents two novel series of antitumor agents in recent patent literature

Oct. 6, 2003

Abraxane exceeds primary efficacy objective in phase III trial

Oct. 6, 2003

Phase III protocol for STR in multiple myeloma agreed under SPA

Oct. 3, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Other news to note for May 1, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: AC Immune, Aptose, Astrazeneca, Bioreference Health, Cardioline,...